Boehringer Ingelheim has announced new data from the ENERGITO and OTEMTO studies of the Stiolto tiotropium/olodaterol Respimat inhaler for the treatment of COPD. The FDA approved Stiolto Respimat in May 2015; in Europe, where the product is known as Spiolto Respimat, BI announced approval by several countries in July 2015. BI previously announced data from OTEMTO 1&2 showing that Stiolto Respimat improves quality of life.
The new data from ENERGITO show increased FEV1 AUC0–12, the primary endpoint, for moderate-to-severe COPD patients using once-daily Stiolto Respimat for six weeks compared to a fluticasone/salmeterol DPI twice daily.
Boehringer Ingelheim VP, Clinical Development & Medical Affairs, Respiratory, Danny McBryan said, “As a leader in COPD care for more than 40 years in the US, we’re encouraged by these new data that further our knowledge of the potential benefits of Stiolto Respimat. Based on the available clinical data, we believe Stiolto Respimat will help address unmet patient needs in the COPD community.”
Read the Boehringer Ingelheim press release.
